Wall Street analysts predict that VERONA PHARMA P/S (NASDAQ:VRNA) will report earnings of ($0.61) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for VERONA PHARMA P/S’s earnings, with estimates ranging from ($0.73) to ($0.50). VERONA PHARMA P/S reported earnings per share of $0.06 in the same quarter last year, which suggests a negative year over year growth rate of 1,116.7%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.
Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow VERONA PHARMA P/S.
VERONA PHARMA P/S (NASDAQ:VRNA) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.04.
A hedge fund recently raised its stake in VERONA PHARMA P/S stock. Wedbush Securities Inc. raised its holdings in VERONA PHARMA P/S (NASDAQ:VRNA) by 75.5% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 24,800 shares of the company’s stock after acquiring an additional 10,670 shares during the quarter. Wedbush Securities Inc. owned approximately 0.19% of VERONA PHARMA P/S worth $161,000 as of its most recent SEC filing. 56.09% of the stock is currently owned by hedge funds and other institutional investors.
VRNA stock opened at $5.10 on Friday. The stock’s 50 day moving average is $5.89. The firm has a market cap of $67.15 million, a PE ratio of -2.52 and a beta of -0.89. VERONA PHARMA P/S has a 1 year low of $5.10 and a 1 year high of $15.70.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Read More: What is the return on assets (ROA) ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.